Ramalingam Compares Third Generation EGFR TKI Osimertinib to Older Agents in NSCLC
Suresh S. Ramalingam, MD, discusses how the EGFR tyrosine kinase inhibitor osimertinib compared with other EGFR inhibitors for patients with EGFR-mutant lung cancer.
Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses how the EGFR tyrosine kinase inhibitor (TKI) osimertinib (Tagrisso) compared with other EGFR inhibitors for patients withEGFR-mutant lung cancer.
As a third-generation EGFR inhibitor, osimertinib is very specific for EGFR compared with other EGFR inhibitors. The tolerability profile is also more favorable because osimertinib has fewer effects on the wildtypeEGFR-bearing cells, says Ramalingam.
Osimertinib also has better CNS penetration than the other EGFR TKIs. Research has shown that 40% to 45% of patients withEGFRmutations will develop brain metastases during the course of their disease at some point, so having an agent like osimertinib which has better CNS penetration is important. Finally, Ramalingam says that osimertinib can inhibit T790M, in addition to exon 19 and exon 21.
For more information from Ramalingam on osimertinib inEGFR-mutant lung cancer:https://www.targetedonc.com/news/updated-flaura-data-support-fda-approval-of-osimertinib-in-egfr-nsclc.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
